Phase II study of first-line combined chemotherapy bevacizumab with modified RPMI regimen for elderly or frail patients with unresectable or metastatic colorectal cancer (OGSG0802) update analysis.
Taroh Satoh
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Yakult Honsha
Takeshi Kato
Honoraria - Chugai Pharma
Motoki Yoshida
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Shigeyoshi Iwamoto
No relevant relationships to disclose
Masato Nakamura
No relevant relationships to disclose
Daisuke Sakai
Research Funding - Chugai Pharma; Yakult Honsha
Masaki Matsuoka
No relevant relationships to disclose
Toshio Otsuji
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose